Impact of Malignancies on Long-Term Survival after Heart Transplantation

Introduction

With the development of new immunosuppressive agents, the majority of transplant recipients are surviving for over a decade, and malignancy has become a major burden on long-term survival. An increased risk of malignancy is well described after heart transplantation (HTx) for both solid tumors and lymphoproliferative disease [1].

References

• 1 Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.  J Heart Lung Transplant. 2007;  26 557-564
• 2 Kirklin J K, Naftel D C, Bourge R C, McGiffin D C, Hill J A, Rodeheffer R J, Jaski B E, Hauptman P J, Weston M, White-Williams C. Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study.  J Thorac Cardiovasc Surg. 2003;  125 881-890
• 3 Taylor D O, Edwards L B, Boucek M M, Trulock E P, Aurora P, Christie J, Dobbels F, Rahmel A O, Keck B M, Hertz M I. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007.  J Heart Lung Transplant. 2007;  26 769-781
• 4 Lehmkuhl H, Dengler T, Hiemann N, Pethig K, Stempfle U, Wagner F. Working Group “Thoracic Transplantation”/German Society for Cardiology .Malignancy in thoracic transplantation: a German nationwide post-HTx malignancy registry. San Francisco, USA; International Society for Heart and Lungtransplantation 2007
• 5 Potaris K, Radovancevic B, Thomas C D, Gregoric I, Vaporciyan A A, Riggs S A, Radovancevic R, Vaughn W K, Frazier O H. Lung cancer after heart transplantation: a 17-year experience.  Ann Thorac Surg. 2005;  79 980-983
• 6 Casadio F, Croci S, D'Errico Grigioni A, Corti B, Grigioni W F, Landuzzi L, Lollini P L. Toward the definition of immunosuppressive regimens with antitumor activity.  Transplant Proc. 2005;  37 2144-2147
• 7 O'Neill J O, Edwards L B, Taylor D O. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.  J Heart Lung Transplant. 2006;  25 1186-1191
• 8 Ulrich C, Euvrard S, Salasche S, Schmook T. Impact of new immunosuppressants on the dermatological outcome of organ transplant patients.  J Am Acad Dermatol March. 2004;  50 (Suppl. 3) P31
• 9 Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report.  Am J Transplant. 2004;  4 222-230
• 10 Ippoliti G, Rinaldi M, Pellegrini C, Viganò M. Incidence of cancer after immunosuppressive treatment for heart transplantation.  Crit Rev Oncol Hematol. 2005;  56 101-113
• 11 Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl H B, Berger F, Hetzer R, Reinke P. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.  J Heart Lung Transplant. 2008;  27 100-105
• 12 Trappe R U, Choquet S, Reinke P, Dreyling M, Mergenthaler H G, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single-agent rituximab.  Transplantation. 2007;  84 1708-1712
• 13 Hauptman P J, Mehra M R. It is time to stop ignoring malignancy in heart transplantation: a call to arms.  J Heart Lung Transplant. 2005;  24 1111-1113